Ascendis Announces Week 52 Data From Open-Label Sentinel Cohort Portion Of reACHin Trial Showing Treatment With Once-Weekly TransCon CNP Provided Stabilization Or Improvement In Foramen Magnum Stenosis And Linear Growth Benefits In Infants With Achondroplasia
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in
Ascendis tested a new medicine for a rare bone condition in babies, and the results showed the medicine helped keep a neck problem stable and helped kids grow taller. When you see medical test results like this, watch whether the company moves forward to the next testing stage, since that tells you if doctors think the medicine is really working.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.